Citadel Advisors
BPTH

Citadel Advisors’s Bio-Path Holdings Inc BPTH Stock Holding History

Citadel Advisors’s Portfolio BPTH Stock Details BPTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-165
Closed -$1.53K – 15782
2023
Q4 		$1.53K Buy
+165
New +$1.74K ﹤0.01% 13809

Other funds holding BPTH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's BPTH Position: Q4 2024 in Review

Citadel Advisors sold out of Bio-Path Holdings Inc (BPTH) in Q4 2024, closing a stake of 10,917 shares — an estimated $9.93K sold.

Citadel Advisors first reported a position in BPTH in Q1 2015 and held it in 12 quarters. The position peaked at $169K in Q2 2021. 22 funds tracked by Wall St. Rank hold BPTH as of Q4 2024.

  • Citadel Advisors reported no remaining Bio-Path Holdings Inc position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 10,917 Bio-Path Holdings Inc shares in Q4 2024, an estimated $9.93K.
  • Citadel Advisors first reported a position in Bio-Path Holdings Inc in Q1 2015 and held it in 12 quarters.
  • Citadel Advisors's Bio-Path Holdings Inc position peaked at $169K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Bio-Path Holdings Inc as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.